Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients who completed the core CACZ885D2307 study (a patient is defined as having completed the core study if they completed the study up to and including the EOS visit with no major protocol deviations in the core).~2. Male and female patients that are ≥ 1 year of age at the time of the roll-over visit.~3. Parent or legal guardian written informed consent must be obtained before any assessment in the extension CACZ885D2307E1 study is performed.~Exclusion criteria:~1. Patients for who continued treatment in the CACZ885D2307E1 extension study is not considered appropriate by the treating physician.~2. Patients who discontinued from the core CACZ885D2307 study~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 4 Years
- Healthy Volunteers: f

Study Arms:
- canakinumab (Type: EXPERIMENTAL): Patients will receive a standard dose at an equivalent of 2 mg/kg s.c. of canakinumab (ACZ885) every 8 weeks. Possible dose and/or dosing regimen adjustments that can be administered include: 4 mg/kg s.c. (every 4 to 8 weeks) 6 mg/kg s.c. (every 4 to 8 weeks) 8 mg/kg s.c. (every 4 to 8 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).